Company Profile
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company provides the research, development, and commercialization of drugs for the treatment of central nervous system disorders.
The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome.
Its portfolio also includes Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease, SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy, SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia, SKL27969 for treatment of advanced solid tumors, SKL13865 clinical trials to treat attention deficit/hyperactivity disorder, and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. Founded in 1993, the company is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.